INS and type 2 diabetes mellitus: In the E-LIFT trial, 50 T2D patients with NAFLD who were at least 40 years old were randomly assigned to receive empagliflozin (10 mg/day) plus their standard medical treatment for T2D, such as metformin and/or insulin, or to receive only their standard treatment without empagliflozin (control group) Their liver fat content was measured using magnetic resonance imaging-proton density fat fraction (MRI-PDFF).